无套内射无矿码免费看黄_亚洲精品嫩草AV在线观看_久久久久久国产精品免费免费男同_正在播放少妇呻吟对白_亚洲日韩欧美成人久久_色哟哟国产精品免费观看_4d肉蒲团之性奴大战奶水_人人妻人人澡人人爽_国产精品熟女在线视频_野外做受三级视频

英國Pro-Cure Therapeutics Limited (Pro-Cure)
從大學(xué)的癌癥研究所內(nèi)部發(fā)展出來的一家企業(yè)，從事前列腺癌基因療法的研究。

Pro-Cure Therapeutics Limited (Pro-Cure) is a UK-based R&D company that is focused on cancer stem cell therapies - with an initial interest in prostate cancer stem cells.

Founded on the work of Professor Norman Maitland and Dr Anne Collins of the Yorkshire Cancer Research (YCR) Cancer Research Unit (CRU) at York University, the Company has identified drug targets for new classes of cancer drugs that fundamentally change the management of prostate cancer by preventing cancer stem cells' ability to initiate new tumours, to prevent recurrence, prevent metastasis and as an effective treatment for drug-resistant forms of prostate cancer.

Pro-Cure seeks alliances with companies to develop new therapeutics against these exciting new targets. Pro-Cure is pursuing MAb approaches to selected targets but targets are also identified that are suited to other therapeutic technologies such as small molecules (different classes of receptors and targets have been identified including common drug targets such as kinases, proteases, etc.), siRNA and peptides. We also have other targets in validation that are suited to antibody therapies and vaccines.